Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.28 (market cap $39.95B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 23.4× Nuvation Bio Inc. Class A Common Stock's market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.2% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| HLN | NUVB | |
|---|---|---|
Market Cap | $39.95B | $1.71B |
Volume | 18,243,581 | 5,448,712 |
Sector | Health | Health |
52-Week High | $11.27 | $9.54 |
52-Week Low | $8.70 | $3.41 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $49.77B | $1.30B |
Dividend Yield | 2.2% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
